Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agios Pharmaceuticals

39.92
-0.0800-0.20%
Post-market: 39.31-0.6100-1.53%18:13 EDT
Volume:429.90K
Turnover:17.23M
Market Cap:2.31B
PE:3.49
High:40.60
Open:40.09
Low:39.65
Close:40.00
Loading ...

Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress

TIPRANKS
·
14 Feb

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Benzinga
·
14 Feb

Agios Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
13 Feb

Agios Pharmaceuticals' Q4 Loss Widens, Revenue Rises

MT Newswires Live
·
13 Feb

Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study

TIPRANKS
·
13 Feb

Agios Pharmaceuticals Q4 Sales $10.70M Beat $9.33M Estimate, Net Loss Of $96.5M Vs. $95.9M YoY, Cash Balance Of $1.5B

Benzinga
·
13 Feb

Agios Pharmaceuticals FY 2024 GAAP EPS $11.64 Beats $11.46 Estimate, Sales $36.50M Beat $35.13M Estimate

Benzinga
·
13 Feb

Agios Pharmaceuticals - Reports Q4 Pyrukynd Net REV of $10.7 Mln

THOMSON REUTERS
·
13 Feb

Press Release: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dow Jones
·
13 Feb

Agios’ Phase 3 Activate-Kids Study of Mitapivat in Children With Pyruvate Kinase (Pk) Deficiency Not Regularly Transfused Met Primary Endpoint

THOMSON REUTERS
·
13 Feb

Agios Pharmaceuticals Inc - Safety Results Consistent With Previous Adult Studies

THOMSON REUTERS
·
13 Feb

Agios Pharmaceuticals Inc - to Submit Marketing Application for Mitapivat in Pediatric Pk Deficiency

THOMSON REUTERS
·
13 Feb

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

GlobeNewswire
·
13 Feb

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

TIPRANKS
·
11 Feb

BofA Securities Trims Price Target on Agios Pharmaceuticals to $54 From $55, Maintains Buy Rating

MT Newswires Live
·
11 Feb

Agios Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $54 From $55

THOMSON REUTERS
·
11 Feb

Bank of America Securities Keeps Their Buy Rating on Agios Pharma (AGIO)

TIPRANKS
·
11 Feb